Akers Biosciences Inc. (AKER)

[leifsmith]

Could be wrong, of course, but I think the merger with MYMD will succeed. There's too much benefit here for AKER to allow it to fail. Main reason for my confidence is that I think Jonnie Williams' work and intentions are genuine. His long-standing collaboration with Johns Hopkins researchers is encouraging.

After the merger, the surviving company will be MYMD, and the stock listing will be MYMD. I'm optimistic that this will be a success.